During the 67th annual meeting of the American Society of Hematology, experts from the HARMONY Alliance Community will be presenting results obtained from research conducted within our Platform
The ASH annual meeting of this year will take place in Orlando, Florida, between December 6th and 9th 2025. We are proud to announce that the three abstracts with results obtained from using data on the HARMONY Platform that were submitted in August were accepted as oral presentations. Here is all the relevant information you need to include on your agendas:
📅 On Saturday 6th
💬 Presentation: Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the HARMONY Platform
📋 Session 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Decoding the Molecular Drivers of response and resistance
⌚ Session time: 9:30 AM – 11:00 AM || Presentation Time: 10:00 AM
📍 Place: OCCC – Valencia Room W415D
On her presentation, Prof. Susan Branford, Head of the Leukaemia lab in the Department of Genetics and Molecular Pathology at SA Pathology will explain the results of the collaboration with iCMLf, in which we investigated the correlation between certain somatic mutations and the development of CML patients.
Learn the deatils following this link: https://submit.hematology.org/program/presentation/676559
💬 Presentation: Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials
📋 Session: 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: From Detection to Decision: MRD as the Compass in AML
⌚ Session time: Saturday 6th 4:00 PM – 5:30 PM || Presentation Time: 4:00 PM
📍 Place: OCCC – Valencia Room W415A
Dr. Jesse Tettero, Ph.D. Postdoctoral Associate. Hourigan Lab, will showcase the results of our work regarding Measurable Residual Disease as a co-primary end-point for Acute Myeloid Leukemia, as well as its potential regulatory implications
Find out the details on the ASH website: https://submit.hematology.org/program/presentation/676433
📅 On Sunday 7th
💬 Presentation: Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia
📋 Session: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: AML Biomarkers in Action: Prognosis, Risk, and Real-World Insights
⌚ Session Time: Sunday 7th 9:30 AM – 11:00 AM || Presentation Time: 9:30 AM
📍 Place: OCCC – Valencia Room W415A
In this session, Dr. Amin Turki will talk about the independent validation of the AML classification developed with the data on the HARMONY Platform, comparing two large cohorts.
More information about this presentation available at: https://submit.hematology.org/program/presentation/672704
Learn more details and stay up to date through the ASH meeting webpage: https://www.hematology.org/meetings/annual-meeting
On top of the oral presentations mentioned above, the HARMONY Alliance Foundation will have its own session during the ELN Breakfast Meeting, which is kindly organized by Prof Dr Rüdiger Hehlmann each year.
📋 ELN Breakfast Meeting – HARMONY Session
⌚ Time: Sunday 7th 7:30 AM – 9:00AM
📍 Place: Renaissance Orlando at Seaworld, 6677 Sea Harbor Drive, Orlando, FL 32821
In the session, different members of our community will provide an update on the different activities of the Foundation and many of the research projects being conducted within the HARMONY Platform, showcasing results and offering an overview of the activities we have envisioned for next year.
For further information on this and other sessions, check the ELN website https://www.leukemia-net.org/
